HKPD vs STEK
Cellyan Biotechnology Co. Ltd. and Stemtech Corp., side by side — 3 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | HKPD | STEK |
|---|---|---|
| Revenue | $20.3M | $2.9M |
| Net income | $-27,056 | $-4.0M |
| Gross margin | 11.9% | 80.3% |
| Net margin | −0.1% | −140.8% |
| Return on equity | −0.6% | · |
| Diluted EPS | −$0.00 | −$0.02 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $499,298 | $-483,583 |
| Equity | $5.0M | $-7.0M |
| Net debt / equity | 0.23× | · |
| Current ratio | 2.99× | 0.04× |
| Revenue CAGR 5y | · | −8.1% |
| Profit CAGR 5y | · | · |
HKPD bills 7.1× the revenue of STEK, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
3 years side by side
| Fiscal year | HKPD | STEK |
|---|---|---|
| FY2024 | $20.3M | $5.1M |
| FY2023 | $16.7M | $4.9M |
| FY2022 | $12.6M | $4.6M |
Bottom line
| Fiscal year | HKPD | STEK |
|---|---|---|
| FY2024 | $-27,056 | $-3.8M |
| FY2023 | $1.3M | $-5.4M |
| FY2022 | $998,196 | $-8.5M |
Standard deviation, each side
STEK's net margin has been more volatile than HKPD's over the 3 comparable fiscal years — 47.9 percentage points of standard deviation against 3.8.
3 of 6 comparable fiscal years — a year missing data on either side is not counted.
Year by year
HKPD led in net margin in every one of the 3 comparable fiscal years — a structural lead, not a recent swing.
3 of 6 comparable fiscal years — a year missing data on either side is not counted.